Original Article
Brief Report
Ovarian Hyperstimulation Syndrome Due to a Mutation in the Follicle-Stimulating Hormone Receptor
N Engl J Med 2003; 349:760-766August 21, 2003
- Article
The ovarian hyperstimulation syndrome most often occurs as an iatrogenic complication of ovarian-stimulation treatments for in vitro fertilization (the incidence of severe forms ranges from 0.5 to 5 percent).1 The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration in a third space.2 Although the presence of human chorionic gonadotropin is invariably associated with the condition, the pathophysiological mechanism remains undefined.3
The overproduction of endogenous chorionic gonadotropin during pregnancy has been associated with spontaneous ovarian hyperstimulation syndrome (also termed hyperreactio luteinalis of the first trimester), as well as with hyperemesis gravidarum and transient gestational thyrotoxicosis.4-7 Transient gestational thyrotoxicosis appears to be due to the promiscuous activation of the thyrotropin receptor by chorionic gonadotropin,5 but the pathogenesis of hyperemesis gravidarum is incompletely delineated.
In 1998, we described a family with recurrent, severe gestational thyrotoxicosis caused by a mutant thyrotropin receptor that had abnormal sensitivity to normal chorionic gonadotropin levels.8 That observation, together with descriptions in the literature of severe cases of spontaneous (sometimes recurrent) ovarian hyperstimulation syndrome with normal levels of chorionic gonadotropin,6 led us to postulate that a mutation in the follicle-stimulating hormone receptor might be associated with ovarian hyperstimulation syndrome. The case we present here defines a mutation in the follicle-stimulating hormone receptor that is associated with recurrent, spontaneous ovarian hyperstimulation syndrome.
Case Report
The clinical aspects of this case have been described previously.9 Briefly, a woman who is now 40 years of age (height, 1.52 m; weight, 69 kg) presented with spontaneous ovarian hyperstimulation syndrome during each of her four pregnancies (Table 1Table 1
Clinical Data Related to the Four Pregnancies Associated with Spontaneous Ovarian Hyperstimulation Syndrome.). A family history revealed that her mother had had uneventful pregnancies (DNA was not available for analysis); the patient's sister is nulligravid, and her father is deceased. During the patient's first pregnancy at 24 years of age, transabdominal ultrasonography at 13 weeks of gestation revealed that both ovaries were multicystic and enlarged. Acne had also developed, as well as increased hair growth on the abdominal wall. The plasma levels of ovarian and adrenal androgens were normal. The diagnosis of theca lutein cysts was made, and the patient was treated conservatively; she delivered a normal, healthy, term female infant weighing 2635 g. The patient's ovaries had returned to their normal size by eight weeks after delivery.During the patient's second pregnancy at 26 years of age, ultrasonography at 14 weeks again revealed enlarged, multicystic ovaries bilaterally. The condition was managed conservatively, and the pregnancy seemed uneventful until the fetus died in utero at 41.5 weeks. Postmortem examination revealed no fetal abnormality. Again, the patient's ovaries had returned to their normal size by 12 weeks after delivery yet appeared polycystic on ultrasonography.
During the patient's third pregnancy at 29 years of age, she presented with dyspnea and painful abdominal distention after nine weeks of amenorrhea. Evaluation revealed hydrothorax, ascites, and enlarged, multicystic ovaries bilaterally, findings consistent with a diagnosis of severe (grade IV) ovarian hyperstimulation syndrome.2 Ultrasonography revealed a viable intrauterine pregnancy. The patient's serum β human chorionic gonadotropin level was 56,200 mIU per milliliter (normal values for 9 to 11 weeks of gestation, 48,000 to 144,000 mIU per milliliter). The thyrotropin level was normal (2 μIU per milliliter). The hematocrit was 39 percent, and the prothrombin time, the activated partial-thromboplastin time, the bleeding time, and platelet count were normal. During the next two weeks, multiple paracenteses yielded 11 liters of ascitic fluid. However, ultrasonography at 10.5 weeks revealed a nonviable fetus. The dead fetus was removed by curettage, and the patient's symptoms improved rapidly. The ovaries had returned to their normal size by eight weeks later.
Two years later, the patient consulted us regarding secondary infertility. At that time, her menstrual cycles occurred at regular 30-day intervals. General physical examination and pelvic examination were normal. Ultrasonography revealed typical polycystic ovaries (Table 1). At day 3 of her menstrual cycle, the follicle-stimulating hormone level was normal (7 IU per liter), and the luteinizing hormone level was elevated (18 IU per liter). She became pregnant without treatment. However, eight weeks into a viable singleton pregnancy, the patient again presented with grade IV ovarian hyperstimulation syndrome. The serum β human chorionic gonadotropin level was normal (101,190 mIU per milliliter), the estradiol level was moderately elevated (3270 pg per milliliter [12,004 pmol per liter]), the progesterone level was elevated (12,200 ng per deciliter [388 nmol per liter]), and the thyrotropin level was normal (1.2 μIU per milliliter). The patient was treated conservatively, and both the size of the ovaries and the ascites gradually decreased during the pregnancy. At term, the patient delivered a healthy male infant weighing 2860 g. Eight weeks after delivery the patient's ovaries had returned to their normal size. The patient provided written informed consent for this study, which was approved by the ethics committee of the Erasme Hospital in Brussels, Belgium.
Methods
Sequencing of the Gene for the Follicle-Stimulating Hormone Receptor
DNA was extracted from peripheral-blood leukocytes, and the sequences of all exons of the gene for the follicle-stimulating hormone receptor together with intron–exon junctions were determined as described by Gromoll et al.,10 with minor modifications (sequences of primers appear in Supplementary Appendix 1, available with the full text of this article at http://www.nejm.org). The sequence of the segment harboring the mutation was determined in the product of two independent polymerase chain reactions (PCRs).
Functional Characterization of the Mutation
The mutation identified in the gene for the follicle-stimulating hormone receptor was introduced into complementary DNA (cDNA) of human wild-type follicle-stimulating hormone receptor inserted in an expression vector (pSVL, Pharmacia) with the use of site-directed mutagenesis (QuickChange, Stratagene).11 The sequence of the segment containing the mutation was verified in both strands.
Plasmids encoding human wild-type follicle-stimulating hormone receptor, luteinizing hormone–chorionic gonadotropin receptor, thyrotropin receptor, or mutant follicle-stimulating hormone receptor were transfected into COS-7 cells, which are derived from fibroblasts from the kidneys of African green monkeys, as described elsewhere.11 Expression on the cell surface was assessed by flow cytometry (FACScan, Becton Dickinson) with mouse monoclonal antibodies (5B2 for follicle-stimulating hormone receptor, 16B5 for luteinizing hormone–chorionic gonadotropin receptor, and BA8 for thyrotropin receptor).12 Forty-eight hours after transfection, the intracellular accumulation of cyclic AMP (cAMP) was measured at base line and after incubation for 60 minutes with various concentrations of recombinant human follicle-stimulating hormone (Puregon, Organon), recombinant human chorionic gonadotropin (Sigma Chemical), or recombinant human thyrotropin (Thyrogen, Genzyme).11
Results
Sequence Determination
Direct sequencing of PCR products amplified from genomic DNA of the patient revealed a heterozygous substitution of adenine for guanine at the first base of codon 567 in exon 10 of the gene for the follicle-stimulating hormone receptor, resulting in the replacement of aspartic acid with asparagine (D567N [numbering begins at the first amino acid of the signal peptide of the protein]; GenBank accession number, M65085) (Figure 1AFigure 1
Detection of the D567N Mutation.). Aspartate 567 is conserved in all three glycoprotein-hormone receptors; it is located at the cytoplasmic extremity of the sixth helix of the transmembrane domain (Figure 2AFigure 2
Functional Characterization of the D567N Mutation.). The mutation destroys a Tsp45I restriction site (Figure 1B), resulting in an easy means of screening for the general population. None of 100 unrelated normal subjects carried the mutation, ruling out the possibility of a common polymorphism.Functional Characterization of the Mutant Receptor
Despite a lower level of expression at the cell surface than that of the wild-type receptor (mean [±SE] expression values, 69±3 percent of the wild-type–receptor expression value), the mutant receptor was found to have basal cAMP accumulation in transiently transfected COS-7 cells that was three times as high as that of the wild-type receptor (Figure 2A). The sensitivity of the mutant receptor to recombinant human follicle-stimulating hormone was identical to that of the wild-type receptor, but the maximal response was slightly greater (Figure 2B). In contrast, although recombinant human chorionic gonadotropin in concentrations of up to 300 IU per milliliter was only slightly effective in cells expressing the wild-type follicle-stimulating hormone receptor, it caused a clear concentration-dependent increase in cAMP accumulation in cells expressing the mutant receptor (Figure 2C). Despite this gain of function in terms of the stimulation of cAMP production by chorionic gonadotropin, the mutant follicle-stimulating hormone receptor remains about 1/1000 as sensitive to this hormone as the wild-type luteinizing hormone–chorionic gonadotropin receptor (Figure 2C). The decrease in the specificity of the mutant receptor was not restricted to chorionic gonadotropin. Indeed, recombinant human thyrotropin, in concentrations of up to 30 mIU per milliliter, also caused a clear concentration-dependent increase in cAMP production in cells containing the mutant follicle-stimulating hormone receptor but only a minimal increase in cells containing the wild-type receptor (Figure 2D).
The binding affinity of the D567N mutant receptor for follicle-stimulating hormone was similar to that of the wild-type receptor (data not shown). No substantial displacement of labeled follicle-stimulating hormone by chorionic gonadotropin or thyrotropin could be observed in binding experiments, whether involving the mutant receptor or the wild-type receptor (data not shown).
Discussion
Deriving from a common ancestor, the hormone-specific beta subunits of the four glycoprotein hormones (thyrotropin, follicle-stimulating hormone, luteinizing hormone, and chorionic gonadotropin) are substantially similar. The three corresponding receptors (thyrotropin receptor, luteinizing hormone–chorionic gonadotropin receptor, and follicle-stimulating hormone receptor) also most likely evolved from a common ancestral gene. These receptors constitute a subfamily of G-protein–coupled receptors characterized by a serpentine, rhodopsin-like domain with seven transmembrane helixes that are responsible for the activation of intracellular regulatory cascades (e.g., the adenylyl cyclase–dependent generation of cAMP, in the present case) and an extracellular domain that is responsible for recognition and binding of specific hormones.13-15 In this evolutionary context, it would be expected that the extremely high level of chorionic gonadotropin achieved during pregnancy in primates could override the barrier of specificity and thus stimulate the thyrotropin or follicle-stimulating hormone receptors — in so-called promiscuous stimulation (Figure 2C).5,16
The substitution of asparagine for aspartate 567 at the cytoplasmic end of transmembrane helix VI (Figure 2A) causes an increase in the basal activity of the mutant receptor, which also becomes abnormally sensitive to both chorionic gonadotropin and thyrotropin. The first characteristic is in accord with the findings that a different substitution of the same residue (D567G), which has been reported in a man,17 and mutations of the homologous residues in other G-protein–coupled receptors have caused an increase in basal activity.18-20 It is more difficult to explain the decreased specificity, since aspartate 567 is clearly located outside of the hormone-binding domain. According to our current model, the activation of glycoprotein hormone receptors would take place in two steps: first, the ligand would bind to the ectodomain (the extracellular portion of the receptor); second, the ligand–ectodomain complex would interact with the serpentine (transmembrane) portion of the receptor and activate it.21 Given the identical ligand-binding characteristics of the wild-type and mutant receptors, the small but definite stimulatory effects of chorionic gonadotropin and thyrotropin on the wild-type follicle-stimulating hormone receptor and the higher maximal response of the mutant receptor to follicle-stimulating hormone lead us to hypothesize that the mutation of aspartate 567 would facilitate the second step by releasing an inhibitory constraint that is normally present in the serpentine domain of all G-protein–coupled receptors.20
On the basis of the observation that the effects of a single amino acid substitution in the follicle-stimulating hormone receptor can closely mimic pharmacologically induced ovarian hyperstimulation syndrome, it is tempting to speculate that there is a parallel between the phenotype of the mutant receptor in vitro and the pathophysiology of the iatrogenic disease: During controlled ovarian stimulation, the administration of exogenous follicle-stimulating hormone induces recruitment and growth of multiple antral follicles, and ovulation is triggered by the administration of human chorionic gonadotropin. The development of the ovarian hyperstimulation syndrome is associated with the sustained luteotropic effect of both exogenously administered chorionic gonadotropin and endogenous placental gonadotropin after implantation.3,22
In our patient, the constitutive activity of the mutant receptor would continuously recruit numerous follicles, which might explain the polycystic appearance of her ovaries as visualized on ultrasonography. During pregnancy, these numerous unluteinized follicles, which, in contrast to the corpus luteum, still express follicle-stimulating hormone receptor,23 would be hyperstimulated by placental chorionic gonadotropin, causing them to enlarge. Thereafter, chorionic gonadotropin, acting at its own receptor, would cause luteinization as well as hypersecretion of vasogenic molecules that might induce a systemic capillary leak and a shift of fluid into a third space.3,24,25
Symptoms in spontaneous cases of ovarian hyperstimulation syndrome appear later than those in iatrogenic cases (at 8 to 14 weeks of pregnancy, as compared with 3 to 8 weeks).1,2,6,7,22 According to our hypothesis, in spontaneous cases, massive enlargement of multiple follicles would be induced through the hyperstimulation of the follicle-stimulating hormone receptor by endogenous chorionic gonadotropin, whereas in iatrogenic cases, it would be induced by exogenous follicle-stimulating hormone before ovulation.
Both the constitutive activity of the mutant receptor and its increased sensitivity to chorionic gonadotropin would be implicated in the generation of spontaneous ovarian hyperstimulation syndrome. Alternatively, the promiscuous activation of the follicle-stimulating hormone receptor by chorionic gonadotropin might be sufficient to induce the condition, as suggested by the spontaneous occurrence of the syndrome in patients with trophoblastic disease.6,7
Our study indicates that inappropriate stimulation of the follicle-stimulating hormone receptor is a key element in the development of ovarian hyperstimulation syndrome, suggesting that the susceptibility to iatrogenic disease might be associated with polymorphisms at the locus of the gene for this receptor.
Supported by the Belgian State, Prime Minister's Office, Service for Sciences, Technology, and Culture; and by grants from the Fonds de la Recherche en Sciences et Médecine, the Fonds National de la Recherche Scientifique, Association Recherche Biomédicale et Diagnostic, and BRAHMS Diagnostica. Dr. Costagliola is a Research Associate at the Belgian Fonds National de la Recherche Scientifique.
Dr. Olatunbosun reports having received lecture fees from Organon and Wyeth–Ayerst and funding from Serono and Bristol-Myers Squibb; Dr. Pierson consulting fees from R.W. Johnson Pharmaceutical Research Institute and lecture fees from Organon and Janssen Ortho; and Dr. Vassart lecture fees and a grant from BRAHMS Diagnostica.
We are indebted to the Department of Medical Genetics for genomic DNA extraction and to Véronique Janssens for expert assistance in molecular and cellular biology.
Source Information
From the Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Faculté de Médecine, Université Libre de Bruxelles (G.S., G.V., S.C.); and the Service de Génétique Médicale (G.S., G.V.) and Clinique de Fertilité (A.D.), Hôpital Erasme — both in Brussels, Belgium; and the Department of Obstetrics, Gynecology, and Reproductive Sciences (O.O., R.P.) and the Reproductive Biology Research Unit (R.P.), College of Medicine, University of Saskatchewan, Saskatoon, Canada.
Address reprint requests to Dr. Vassart at the IRIBHM, 808 Rte. de Lennik, B-1070 Brussels, Belgium, or at gvassart@ulb.ac.be.
- References
References
1
Delvigne A ,Rozenberg S . Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-577
CrossRef | Web of Science | Medline2
Golan A ,Ron-el R ,Herman A ,Soffer Y ,Weinraub Z ,Caspi E . Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-440
CrossRef | Medline3
Elchalal U ,Schenker JG . The pathophysiology of ovarian hyperstimulation syndrome -- views and ideas. Hum Reprod 1997;12:1129-1137
CrossRef | Web of Science | Medline4
Furneaux EC ,Langley-Evans AJ ,Langley-Evans SC . Nausea and vomiting of pregnancy: endocrine basis and contribution to pregnancy outcome. Obstet Gynecol Surv 2001;56:775-782
CrossRef | Web of Science | Medline5
Glinoer D . The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997;18:404-433
CrossRef | Web of Science | Medline6
Ludwig M ,Gembruch U ,Bauer O ,Diedrich K . Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS. Hum Reprod 1998;13:2082-2087
CrossRef | Web of Science | Medline7
Wajda KJ ,Lucas JG ,Marsh WL Jr . Hyperreactio luteinalis: benign disorder masquerading as an ovarian neoplasm. Arch Pathol Lab Med 1989;113:921-925
Web of Science | Medline8
Rodien P ,Bremont C ,Sanson M-LR , et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med 1998;339:1823-1826
Full Text | Web of Science | Medline9
Olatunbosun OA ,Gilliland B ,Brydon LA ,Chizen DR ,Pierson RA . Spontaneous ovarian hyperstimulation syndrome in four consecutive pregnancies. Clin Exp Obstet Gynecol 1996;23:127-132
Medline10
Gromoll J ,Brocker M ,Derwahl M ,Hoppner W . Detection of mutations in glycoprotein hormone receptors. Methods 2000;21:83-97
CrossRef | Web of Science | Medline11
Costagliola S ,Panneels V ,Bonomi M , et al. Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors. EMBO J 2002;21:504-513
CrossRef | Web of Science | Medline12
Costagliola S ,Rodien P ,Many MC ,Ludgate M ,Vassart G . Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. J Immunol 1998;160:1458-1465
Web of Science | Medline13
Remy JJ ,Nespoulous C ,Grosclaude J , et al. Purification and structural analysis of a soluble human chorionogonadotropin hormone-receptor complex. J Biol Chem 2001;276:1681-1687
Web of Science | Medline14
Schmidt A ,MacColl R ,Lindau-Shepard B ,Buckler DR ,Dias JA . Hormone-induced conformational change of the purified soluble hormone binding domain of follitropin receptor complexed with single chain follitropin. J Biol Chem 2001;276:23373-23381
CrossRef | Web of Science | Medline15
Cornelis S ,Uttenweiler-Joseph S ,Panneels V ,Vassart G ,Costagliola S . Purification and characterization of a soluble bioactive amino-terminal extracellular domain of the human thyrotropin receptor. Biochemistry 2001;40:9860-9869
CrossRef | Web of Science | Medline16
Schubert RL ,Narayan P ,Puett D . Specificity of cognate ligand-receptor interactions: fusion proteins of human chorionic gonadotropin and the heptahelical receptors for human luteinizing hormone, thyroid-stimulating hormone, and follicle-stimulating hormone. Endocrinology 2003;144:129-137
CrossRef | Web of Science | Medline17
Gromoll J ,Simoni M ,Nieschlag E . An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. J Clin Endocrinol Metab 1996;81:1367-1370
CrossRef | Web of Science | Medline18
Parma J ,Duprez L ,Van Sande J , et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993;365:649-651
CrossRef | Web of Science | Medline19
Shenker A . Activating mutations of the lutropin choriogonadotropin receptor in precocious puberty. Receptors Channels 2002;8:3-18
CrossRef | Medline20
Meng EC ,Bourne HR . Receptor activation: what does the rhodopsin structure tell us? Trends Pharmacol Sci 2001;22:587-593
CrossRef | Web of Science | Medline21
Vlaeminck-Guillem V ,Ho SC ,Rodien P ,Vassart G ,Costagliola S . Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol 2002;16:736-746
CrossRef | Web of Science | Medline22
Mathur RS ,Akande AV ,Keay SD ,Hunt LP ,Jenkins JM . Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901-907
CrossRef | Web of Science | Medline23
Simoni M ,Gromoll J ,Nieschlag E . The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev 1997;18:739-773
CrossRef | Web of Science | Medline24
Levin ER ,Rosen GF ,Cassidenti DL , et al. Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome. J Clin Invest 1998;102:1978-1985
CrossRef | Web of Science | Medline25
Delbaere A ,Bergmann PJ ,Gervy-Decoster C , et al. Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation. Fertil Steril 1997;67:1038-1045
CrossRef | Web of Science | Medline
- Citing Articles (53)
Citing Articles
1
Costantino Di Carlo, Fabiana Savoia, Cinzia Ferrara, Giovanni A. Tommaselli, Giuseppe Bifulco, Carmine Nappi. (2012) Case report: a most peculiar family with spontaneous, recurrent ovarian hyperstimulation syndrome. Gynecological Endocrinology1-3
CrossRef2
K.M.J. Menon, Bindu Menon. (2012) Structure, Function and Regulation of Gonadotropin Receptors- A Perspective. Molecular and Cellular Endocrinology
CrossRef3
Maria D Lalioti. (2011) Impact of follicle stimulating hormone receptor variants in fertility. Current Opinion in Obstetrics and Gynecology 23:3, 158-167
CrossRef4
Gilbert Vassart, Sabine Costagliola. (2011) G protein-coupled receptors: mutations and endocrine diseases. Nature Reviews Endocrinology 7:6, 362-372
CrossRef5
G. Vassart. (2011) Cloning of the TSH receptor: The story from a Brussels perspective. Annales d'Endocrinologie 72:2, 55-59
CrossRef6
A. Delabaere, X. Tran, K. Jardon, J.-L. Pouly, N. Bourdel. (2011) Syndrome d’hyperstimulation ovarienne spontanée dans un contexte gravidique avec hypothyroïdie. Gynécologie Obstétrique & Fertilité 39:3, e64-e67
CrossRef7
Jing Shu, Lili Xing, Lingyan Zhang, Suhua Fang, Hefeng Huang. (2011) Ignored adult primary hypothyroidism presenting chiefly with persistent ovarian cysts: a need for increased awareness. Reproductive Biology and Endocrinology 9:1, 119
CrossRef8
Ursula B. Kaiser. 2011. Gonadotropin Hormones. , 205-260.
CrossRef9
Lisa C. Grossman, Konstantinos G. Michalakis, Hyacinth Browne, Mark D. Payson, James H. Segars. (2010) The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome. Fertility and Sterility 94:4, 1392-1398
CrossRef10
M. Dieterich, M. Bolz, T. Reimer, S. Costagliola, B. Gerber. (2010) Two different entities of spontaneous ovarian hyperstimulation in a woman with FSH receptor mutation. Reproductive BioMedicine Online 20:6, 751-758
CrossRef11
Amla Kuechler, Berthold P Hauffa, Angela Köninger, Gunnar Kleinau, Beate Albrecht, Bernhard Horsthemke, Jörg Gromoll. (2010) An unbalanced translocation unmasks a recessive mutation in the follicle-stimulating hormone receptor (FSHR) gene and causes FSH resistance. European Journal of Human Genetics 18:6, 656-661
CrossRef12
Valerie A. Arboleda, Alice A. Fleming, Eric Vilain. 2010. Disorders of Sex Development. , 227-243.
CrossRef13
A. O. Shpakov, E. A. Shpakova. (2009) Low-molecular regulators of polypeptide hormone receptors containing LGR-repeats. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 3:4, 351-360
CrossRef14
Veerle Vloeberghs, Karen Peeraer, Anne Pexsters, Thomas D'Hooghe. (2009) Ovarian hyperstimulation syndrome and complications of ART. Best Practice & Research Clinical Obstetrics & Gynaecology 23:5, 691-709
CrossRef15
Manmohan K Kamboj,, Chaitanya K Musham,. (2009) Case presentation of hypothyroidism with extreme short stature and early puberty. International Journal on Disability and Human Development 8:3, 317-320
CrossRef16
Baris Ata, Togas Tulandi. (2009) Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment. Expert Review of Obstetrics & Gynecology 4:3, 299-311
CrossRef17
Andrea Hunold, Gerhard Alzen, Stefan A. Wudy, Renate Bluetters-Sawatzki, Eva Landmann, Alfred Reiter, Hans-Joachim Wagner. (2009) Ovarian tumor in a 12-year old female with severe hypothyroidism: A case of Van Wyk and Grumbach syndrome. Pediatric Blood & Cancer 52:5, 677-679
CrossRef18
K O'Brien, E Lazar, A Athanassiou, V Ravnikar. (2009) Ovarian hyperstimulation syndrome associated with fetal trisomy 21. Journal of Perinatology 29:5, 388-390
CrossRef19
Camil Castelo-Branco, Marta del Pino, Esther Valladares. (2009) Ovarian hyperstimulation, hyperprolactinaemia and LH gonadotroph adenoma. Reproductive BioMedicine Online 19:2, 153-155
CrossRef20
Botros Rizk. (2009) Genetics of ovarian hyperstimulation syndrome. Reproductive BioMedicine Online 19:1, 14-27
CrossRef21
Mario Ascoli, David Puett. 2009. The Gonadotropin Hormones and Their Receptors. , 35-55.
CrossRef22
Cristina Lussiana, Benedetta Guani, Caterina Mari, Gabriella Restagno, Marco Massobrio, Alberto Revelli. (2008) Mutations and Polymorphisms of the FSH Receptor (FSHR) Gene. Obstetrical & Gynecological Survey 63:12, 785-795
CrossRef23
Brian J. Arey. (2008) Allosteric modulators of glycoprotein hormone receptors: discovery and therapeutic potential. Endocrine 34:1-3, 1-10
CrossRef24
Rachel Michaelson-Cohen, Gheona Altarescu, Uziel Beller, Renat Reens, Tamar Halevy-Shalem, Talia Eldar-Geva. (2008) Does elevated human chorionic gonadotropin alone trigger spontaneous ovarian hyperstimulation syndrome?. Fertility and Sterility 90:5, 1869-1874
CrossRef25
Henry F. Vischer, Joke C.M. Granneman, Pim J. Koelink, Rute B. Marques, Jan Bogerd. (2008) Identification of a luteinizing hormone-selective determinant in the exodomain of a follicle-stimulating hormone receptor. General and Comparative Endocrinology 156:3, 490-498
CrossRef26
Racine N. Edwards-Silva, Christina S. Han, Yen Hoang, Lee-Chuan Kao. (2008) Spontaneous Ovarian Hyperstimulation in a Naturally Conceived Pregnancy With Uncontrolled Hypothyroidism. Obstetrics & Gynecology 111:2, Part 2, 498-501
CrossRef27
Anne De Leener, Gianluigi Caltabiano, Sanly Erkan, Mehmet Idil, Gilbert Vassart, Leonardo Pardo, Sabine Costagliola. (2008) Identification of the first germline mutation in the extracellular domain of the follitropin receptor responsible for spontaneous ovarian hyperstimulation syndrome. Human Mutation 29:1, 91-98
CrossRef28
ALAN M. RICE, SCOTT A. RIVKEES. 2008. Receptor Transduction of Hormone Action. , 26-73.
CrossRef29
Annalisa Panico, Gelsy Arianna Lupoli, Francesco Fonderico, Sara Colarusso, Francesca Marciello, Maria Rita Poggiano, Michela Del Prete, Raffaele Magliulo, Paolo Iervolino, Giovanni Lupoli. (2007) Multiple Ovarian Cysts in a Young Girl with Severe Hypothyroidism. Thyroid 17:12, 1289-1293
CrossRef30
H. Binder, G. Griesinger, L. Kiesel. (2007) Ovarielles Überstimulationssyndrom. Gynäkologische Endokrinologie 5:4, 203-211
CrossRef31
Barry Hahn. (2007) Ovarian Hyperstimulation Syndrome. The Journal of Emergency Medicine 33:2, 191-192
CrossRef32
Erja Kerkelä, Heli Skottman, Barbro Friden, Kerstin Bjuresten, Juha Kere, Outi Hovatta. (2007) Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertility and Sterility 87:3, 603-606
CrossRef33
Martine J. Smit, Henry F. Vischer, Remko A. Bakker, Aldo Jongejan, Henk Timmerman, Leonardo Pardo, Rob Leurs. (2007) Pharmacogenomic and Structural Analysis of Constitutive G Protein–Coupled Receptor Activity. Annual Review of Pharmacology and Toxicology 47:1, 53-87
CrossRef34
Win Lin, Michael P. Bernard, Donghui Cao, Rebecca V. Myers, John E. Kerrigan, William R. Moyle. (2007) Follitropin receptors contain cryptic ligand binding sites. Molecular and Cellular Endocrinology 260-262, 83-92
CrossRef35
Stephen M. Rosenthal, Stephen E. Gitelman, Gabriel A. Vargas, Brian J. Feldman. (2007) Gain-of-Function Mutations in the V2 Vasopressin Receptor. Hormone Research 67:1, 121-125
CrossRef36
Liselotte Mettler, Antonio Garzon, Heidi Kühling-von Kaisenberg, Constantin S von Kaisenberg. (2006) Ovarian surgery and follicular reserve. Expert Review of Endocrinology & Metabolism 1:6, 743-752
CrossRef37
Anne Delbaere, Guillaume Smits, Gilbert Vassart, Sabine Costagliola. (2006) Genetic predictors of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Nature Clinical Practice Endocrinology & Metabolism 2:11, 590-591
CrossRef38
B.A. Rodrigues, J.L. Rodrigues. (2006) Responses of canine oocytes to in vitro maturation and in vitro fertilization outcome. Theriogenology 66:6-7, 1667-1672
CrossRef39
Francisco J. Morón, Francisco de Castro, Jose L. Royo, Luis Montoro, Emilia Mira, María E. Sáez, Luis M. Real, Alejandro González, Santos Mañes, Agustín Ruiz. (2006) Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenetics and Genomics 16:7, 485-495
CrossRef40
Ilpo Huhtaniemi. (2006) Mutations along the pituitary–gonadal axis affecting sexual maturation: Novel information from transgenic and knockout mice. Molecular and Cellular Endocrinology 254-255, 84-90
CrossRef41
Georg Griesinger, Konstantinos Dafopoulos, Askan Schultze-Mosgau, Wolfgang Jelkmann, Soeren Otte, Dagmar Diesing, Klaus Diedrich. (2006) Vascular endothelial growth factor response to exogenous chorionic gonadotropic hormone in the luteal phase of women with a history of severe ovarian hyperstimulation syndrome. Archives of Gynecology and Obstetrics 274:1, 29-33
CrossRef42
Su-Chin Ho, Sui-Sin Goh, Qing Su, Daphne Hsu-Chin Khoo. (2005) Cysteine 390 mutation of the TSH receptor modulates its ectodomain as an inverse agonist on the serpentine domain with decrease in basal constitutive activity. Molecular and Cellular Endocrinology 245:1-2, 158-168
CrossRef43
Jörg Gromoll, Manuela Simoni. (2005) Genetic complexity of FSH receptor function. Trends in Endocrinology & Metabolism 16:8, 368-373
CrossRef44
Francisco de Castro, Francisco J Morón, Luis Montoro, Luis M Real, Agustín Ruiz. (2005) Pharmacogenetics of controlled ovarian hyperstimulation. Pharmacogenomics 6:6, 629-637
CrossRef45
Catarina Brasil d’Alva, Paulo Serafini, Eduardo Motta, Maria Beatriz da Fonte Kohek, Ana Claudia Latronico, Berenice Bilharinho Mendonca. (2005) Absence of follicle-stimulating hormone receptor activating mutations in women with iatrogenic ovarian hyperstimulation syndrome. Fertility and Sterility 83:6, 1695-1699
CrossRef46
Karina Berger, Haroldo Souza, Vinicius Nahime Brito, Catarina Brasil d'Alva, Berenice Bilharinho Mendonca, Ana Claudia Latronico. (2005) Clinical and hormonal features of selective follicle-stimulating hormone (FSH) deficiency due to FSH beta-subunit gene mutations in both sexes. Fertility and Sterility 83:2, 466-470
CrossRef47
James A. Dias. (2005) Endocrinology: Fertility hormone in repose. Nature 433:7023, 203-204
CrossRef48
Tsutomu Takeuchi, Nobuya Mine, Sayaka Okudaira, Toyohiko Kuwajima, Zuisei Hayashi, Yoshiki Wakaomi, Shunji Suzuki. (2005) A Case of Hyperreactio Luteinalis Complicated by Pedicle Torsion at 30 Weeks' Gestation. Nihon Ika Daigaku Igakkai Zasshi 1:4, 175-179
CrossRef49
Torsten Schöneberg, Angela Schulz, Heike Biebermann, Thomas Hermsdorf, Holger Römpler, Katrin Sangkuhl. (2004) Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacology & Therapeutics 104:3, 173-206
CrossRef50
André Lacroix, Valérie Baldacchino, Isabelle Bourdeau, Pavel Hamet, Johanne Tremblay. (2004) Cushing's syndrome variants secondary to aberrant hormone receptors. Trends in Endocrinology & Metabolism 15:8, 375-382
CrossRef51
J AVECILLAS, T FALCONE, A ARROLIGA. (2004) Ovarian hyperstimulation syndrome. Critical Care Clinics 20:4, 679-695
CrossRef52
Ri-Cheng Chian, Jin-Ho Lim, Seang-Lin Tan. (2004) State of the art in in-vitro oocyte maturation. Current Opinion in Obstetrics and Gynecology 16:3, 211-219
CrossRef53
Kaiser, Ursula Brigitte, . (2003) The Pathogenesis of the Ovarian Hyperstimulation Syndrome. New England Journal of Medicine 349:8, 729-732
Full Text
